MDS Pharma Services has been ranked the top contract research organization (CRO) in Europe in a survey of clinical trial investigators by Thomson CenterWatch.

“This recognition adds to MDS Pharma Services’ reputation as a world-class, market-leading provider of drug discovery and development solutions, and attests to our commitment to continuously raising the bar to better serve our clients,” said David Spaight, president, MDS Pharma Services.

MDS Pharma Services earned the top score for CROs in CenterWatch’s survey of 356 European investigative sites where front-line researchers conduct trials. Investigators were asked to rate the CROs they have worked with over the past two years on a wide range of attributes. 79% of those surveyed gave MDS Pharma Services either “Good” or “Excellent” ratings, and the business received “Excellent” ratings in 14 of 28 attribute areas—more than any other CRO.

MDS Pharma Services was rated “Excellent” in the area of “Organization and Preparation” by 54% of the responding sites. This was the most desired attribute in a CRO, with 83% of respondents rating it as “very important.” The company also out-scored other CROs in every sub- attribute in this category.